Personal tools

Coexpression cluster:C166: Difference between revisions

From FANTOM5_SSTAR

Jump to: navigation, search
No edit summary
No edit summary
Line 6: Line 6:
|ontology_enrichment_disease=
|ontology_enrichment_disease=
|ontology_enrichment_uberon=UBERON:0002405!3.60e-28!115;UBERON:0002371!2.78e-27!80;UBERON:0002193!2.45e-26!112;UBERON:0002390!9.08e-26!102;UBERON:0003061!9.08e-26!102;UBERON:0001474!1.27e-23!86;UBERON:0004765!5.20e-20!101;UBERON:0001434!5.20e-20!101;UBERON:0003081!2.56e-13!216;UBERON:0002204!2.26e-12!167;UBERON:0007023!8.00e-10!115;UBERON:0000467!2.01e-08!625;UBERON:0000480!2.32e-08!626;UBERON:0000479!1.73e-07!787;UBERON:0000062!3.43e-07!511
|ontology_enrichment_uberon=UBERON:0002405!3.60e-28!115;UBERON:0002371!2.78e-27!80;UBERON:0002193!2.45e-26!112;UBERON:0002390!9.08e-26!102;UBERON:0003061!9.08e-26!102;UBERON:0001474!1.27e-23!86;UBERON:0004765!5.20e-20!101;UBERON:0001434!5.20e-20!101;UBERON:0003081!2.56e-13!216;UBERON:0002204!2.26e-12!167;UBERON:0007023!8.00e-10!115;UBERON:0000467!2.01e-08!625;UBERON:0000480!2.32e-08!626;UBERON:0000479!1.73e-07!787;UBERON:0000062!3.43e-07!511
|pathway_enrichment=6.08120276742328e-05;0.0384940135177894;4;156;Phagosome (KEGG):04145
}}
}}

Revision as of 14:55, 13 July 2012


Full id: C166_Macrophage_Monocytederived_Dendritic_adipose_lymph_CD14_lung



Phase1 CAGE Peaks

Hg19::chr10:80737664..80737698,-p@chr10:80737664..80737698
-
Hg19::chr10:82173423..82173439,+p5@FAM213A
Hg19::chr10:82173440..82173452,+p11@FAM213A
Hg19::chr11:118087684..118087694,-p@chr11:118087684..118087694
-
Hg19::chr11:118087713..118087733,-p@chr11:118087713..118087733
-
Hg19::chr11:118087749..118087766,-p@chr11:118087749..118087766
-
Hg19::chr11:122650064..122650075,+p15@UBASH3B
Hg19::chr11:122650109..122650120,+p14@UBASH3B
Hg19::chr11:122650146..122650175,+p10@UBASH3B
Hg19::chr11:128774561..128774596,-p1@C11orf45
Hg19::chr11:21934096..21934106,+p@chr11:21934096..21934106
+
Hg19::chr11:21934119..21934129,+p@chr11:21934119..21934129
+
Hg19::chr11:21934135..21934146,+p@chr11:21934135..21934146
+
Hg19::chr11:22174975..22174980,+p@chr11:22174975..22174980
+
Hg19::chr11:58959504..58959511,+p@chr11:58959504..58959511
+
Hg19::chr11:58959543..58959563,+p@chr11:58959543..58959563
+
Hg19::chr11:58959610..58959620,+p@chr11:58959610..58959620
+
Hg19::chr11:60718699..60718724,-p13@SLC15A3
Hg19::chr11:60719430..60719439,-p24@SLC15A3
Hg19::chr11:62344767..62344782,-p3@TUT1
Hg19::chr11:63964388..63964398,+p16@STIP1
Hg19::chr11:63964439..63964450,+p14@STIP1
Hg19::chr12:14721192..14721202,-p8@PLBD1
Hg19::chr12:16505660..16505685,-p@chr12:16505660..16505685
-
Hg19::chr12:26484990..26485000,-p@chr12:26484990..26485000
-
Hg19::chr12:4388020..4388039,+p9@CCND2
Hg19::chr12:4388045..4388063,+p18@CCND2
Hg19::chr12:49582225..49582269,-p7@TUBA1A
Hg19::chr12:53224364..53224373,-p2@KRT79
Hg19::chr12:56120803..56120814,-p38@CD63
Hg19::chr12:56120838..56120848,-p31@CD63
Hg19::chr13:113951188..113951191,+p21@LAMP1
Hg19::chr13:49086093..49086111,-p@chr13:49086093..49086111
-
Hg19::chr15:77308164..77308175,+p10@PSTPIP1
Hg19::chr15:77308178..77308193,+p11@PSTPIP1
Hg19::chr15:80469727..80469736,+p8@FAH
Hg19::chr15:80469741..80469772,+p6@FAH
Hg19::chr15:83779343..83779358,-p@chr15:83779343..83779358
-
Hg19::chr17:25958114..25958129,+p3@LGALS9
Hg19::chr17:4642833..4642875,-p3@CXCL16
Hg19::chr17:62315972..62315978,-p@chr17:62315972..62315978
-
Hg19::chr17:75276245..75276249,+p@chr17:75276245..75276249
+
Hg19::chr19:3785229..3785244,-p5@MATK
Hg19::chr19:3785250..3785292,-p3@MATK
Hg19::chr19:45418067..45418076,+p7@APOC1
Hg19::chr19:6680235..6680290,-p4@C3
Hg19::chr1:111050807..111050828,+p@chr1:111050807..111050828
+
Hg19::chr1:111050845..111050854,+p@chr1:111050845..111050854
+
Hg19::chr1:111052907..111052935,-p@chr1:111052907..111052935
-
Hg19::chr1:111058061..111058076,+p@chr1:111058061..111058076
+
Hg19::chr1:156510852..156510859,-p@chr1:156510852..156510859
-
Hg19::chr1:156510877..156510889,-p@chr1:156510877..156510889
-
Hg19::chr1:203155503..203155528,-p@chr1:203155503..203155528
-
Hg19::chr1:203198790..203198807,-p1@CHIT1
Hg19::chr1:27962025..27962032,-p15@FGR
Hg19::chr1:54707213..54707231,-p@chr1:54707213..54707231
-
Hg19::chr1:54707235..54707253,-p@chr1:54707235..54707253
-
Hg19::chr1:54707911..54707917,-p@chr1:54707911..54707917
-
Hg19::chr1:54707929..54707943,-p@chr1:54707929..54707943
-
Hg19::chr1:54707952..54707973,-p@chr1:54707952..54707973
-
Hg19::chr1:54707979..54707987,-p@chr1:54707979..54707987
-
Hg19::chr20:1875003..1875020,+p20@SIRPA
Hg19::chr20:33462829..33462852,+p5@ACSS2
Hg19::chr20:33462854..33462864,+p10@ACSS2
Hg19::chr20:33462888..33462894,+p12@ACSS2
Hg19::chr20:44645128..44645150,+p@chr20:44645128..44645150
+
Hg19::chr20:44645159..44645166,+p@chr20:44645159..44645166
+
Hg19::chr20:45179283..45179298,-p1@C20orf123
Hg19::chr2:217362648..217362677,+p3@RPL37A
Hg19::chr2:9562702..9562734,-p5@ITGB1BP1
Hg19::chr2:96782206..96782211,-p3@ADRA2B
Hg19::chr2:97012141..97012156,+p@chr2:97012141..97012156
+
Hg19::chr3:105717313..105717328,+p@chr3:105717313..105717328
+
Hg19::chr3:129334636..129334653,-p1@BC025331
Hg19::chr3:188665020..188665032,+p10@TPRG1
Hg19::chr3:196046974..196046977,-p@chr3:196046974..196046977
-
Hg19::chr3:196065248..196065267,-p1@TM4SF19
Hg19::chr4:48807155..48807187,+p13@OCIAD1
Hg19::chr4:682935..682946,-p2@MFSD7
Hg19::chr5:137330846..137330858,-p@chr5:137330846..137330858
-
Hg19::chr5:147789958..147789969,+p5@FBXO38
Hg19::chr6:160183931..160183971,+p@chr6:160183931..160183971
+
Hg19::chr6:164082461..164082467,-p@chr6:164082461..164082467
-
Hg19::chr6:164082471..164082476,-p@chr6:164082471..164082476
-
Hg19::chr6:164082477..164082487,-p@chr6:164082477..164082487
-
Hg19::chr6:33111201..33111222,-p1@HLA-DPA3
Hg19::chr6:4346987..4346998,-p@chr6:4346987..4346998
-
Hg19::chr6:4347006..4347027,-p@chr6:4347006..4347027
-
Hg19::chr6:46700055..46700067,-p@chr6:46700055..46700067
-
Hg19::chr7:128543401..128543428,-p2@KCP
Hg19::chr7:137308..137321,+p@chr7:137308..137321
+
Hg19::chr7:137336..137341,+p@chr7:137336..137341
+
Hg19::chr7:139762438..139762447,-p4@PARP12
Hg19::chr7:150477549..150477560,-p@chr7:150477549..150477560
-
Hg19::chr7:73507534..73507583,+p2@LIMK1
Hg19::chr8:102216925..102216938,-p7@ZNF706
Hg19::chr8:105670277..105670285,-p@chr8:105670277..105670285
-
Hg19::chr8:18680942..18680953,-p@chr8:18680942..18680953
-
Hg19::chr8:87111132..87111146,+p1@ATP6V0D2
Hg19::chr9:115945404..115945413,-p@chr9:115945404..115945413
-
Hg19::chr9:124030049..124030099,+p7@GSN
Hg19::chr9:86983624..86983647,-p2@SLC28A3
Hg19::chr9:86983657..86983666,-p4@SLC28A3
Hg19::chr9:86983667..86983668,-p11@SLC28A3
Hg19::chrX:149867720..149867743,+p@chrX:149867720..149867743
+


Enriched pathways on this co-expression cluster<b>Summary:</b><br>Canonical pathway gene sets were compiled from Reactome, Wikipathways and KEGG. For the major signaling pathways, the transcriptionally-regulated genes (downstream targets) were obtained from Netpath. Combined, the canonical pathways and downstream targets totaled 489 human gene sets. The corresponding M. musculus gene sets were inferred by homology using the HomoloGene database. Enrichment for each of the canonical 489 pathways and gene sets included in the co-expression cluster was assessed by the hypergeometric probability. The resulting P values were also then adjusted by the Benjamini-Hochberg method for multiple comparisons.<br><b>Analyst: </b>Emmanuel Dimont<br><br>link to source dataset<br>data

p.valueFDRnGenesnPathwayName
6.08120276742328e-050.03849401351778944156Phagosome (KEGG):04145



Enriched Gene Ontology terms on this co-expression cluster<b>Summary:</b> Results for GOStat analysis on co-expressed clusters. Each cluster with promoters mapping to at least two different genes was analysed with GOStat (PMID: 14962934) with default parameter. <br><b>Analyst:</b> Erik Arner<br><br>link to source dataset<br>data

GO IDGO nameFDR corrected p-value
GO:0005765lysosomal membrane0.00512780967323701
GO:0005774vacuolar membrane0.00512780967323701
GO:0044437vacuolar part0.00512780967323701
GO:0005764lysosome0.00512780967323701
GO:0000323lytic vacuole0.00512780967323701
GO:0005773vacuole0.00743018613799899
GO:0045807positive regulation of endocytosis0.0110236329171431
GO:0030100regulation of endocytosis0.0329666922785616
GO:0048518positive regulation of biological process0.0329666922785616
GO:0051050positive regulation of transport0.0329666922785616
GO:0004715non-membrane spanning protein tyrosine kinase activity0.0329666922785616
GO:0005737cytoplasm0.0329666922785616
GO:0005768endosome0.0329666922785616
GO:0050265RNA uridylyltransferase activity0.0329666922785616
GO:0010324membrane invagination0.0329666922785616
GO:0006897endocytosis0.0329666922785616
GO:0005770late endosome0.037051496732088
GO:0001798positive regulation of type IIa hypersensitivity0.0419341731288713
GO:0002894positive regulation of type II hypersensitivity0.0419341731288713
GO:0001796regulation of type IIa hypersensitivity0.0419341731288713
GO:0002886regulation of myeloid leukocyte mediated immunity0.0419341731288713
GO:0002445type II hypersensitivity0.0419341731288713
GO:0001794type IIa hypersensitivity0.0419341731288713
GO:0002888positive regulation of myeloid leukocyte mediated immunity0.0419341731288713
GO:0002892regulation of type II hypersensitivity0.0419341731288713
GO:0048522positive regulation of cellular process0.0424802110626503
GO:0016044membrane organization and biogenesis0.0424802110626503
GO:0005534galactose binding0.0424802110626503
GO:0002712regulation of B cell mediated immunity0.0424802110626503
GO:0002863positive regulation of inflammatory response to antigenic stimulus0.0424802110626503
GO:0002885positive regulation of hypersensitivity0.0424802110626503
GO:0002866positive regulation of acute inflammatory response to antigenic stimulus0.0424802110626503
GO:0002675positive regulation of acute inflammatory response0.0424802110626503
GO:0002889regulation of immunoglobulin mediated immune response0.0424802110626503
GO:0002891positive regulation of immunoglobulin mediated immune response0.0424802110626503
GO:0002714positive regulation of B cell mediated immunity0.0424802110626503
GO:0045737positive regulation of cyclin-dependent protein kinase activity0.0424802110626503
GO:0051179localization0.0427484246496105
GO:0044440endosomal part0.0427484246496105
GO:0010008endosome membrane0.0427484246496105
GO:0004713protein-tyrosine kinase activity0.0427484246496105
GO:0048247lymphocyte chemotaxis0.0427484246496105
GO:0051014actin filament severing0.0427484246496105
GO:0002861regulation of inflammatory response to antigenic stimulus0.0427484246496105
GO:0002673regulation of acute inflammatory response0.0427484246496105
GO:0004938alpha2-adrenergic receptor activity0.0427484246496105
GO:0002864regulation of acute inflammatory response to antigenic stimulus0.0427484246496105
GO:0002883regulation of hypersensitivity0.0427484246496105
GO:0004334fumarylacetoacetase activity0.0427484246496105
GO:0051258protein polymerization0.0446980703271029
GO:0005415nucleoside:sodium symporter activity0.0484642556070935
GO:0006572tyrosine catabolic process0.0484642556070935
GO:0008061chitin binding0.0484642556070935
GO:0001882nucleoside binding0.0484642556070935
GO:0051049regulation of transport0.049824750361269
GO:0044464cell part0.049824750361269
GO:0045773positive regulation of axon extension0.049824750361269
GO:0002437inflammatory response to antigenic stimulus0.049824750361269
GO:0016823hydrolase activity, acting on acid carbon-carbon bonds, in ketonic substances0.049824750361269
GO:0002524hypersensitivity0.049824750361269
GO:0016822hydrolase activity, acting on acid carbon-carbon bonds0.049824750361269
GO:0015198oligopeptide transporter activity0.049824750361269
GO:0002438acute inflammatory response to antigenic stimulus0.049824750361269



Enriched sample ontology terms on this co-expression cluster<b>Summary:</b>To summarize promoter activities (expression profile of a TSS region) across ~1000 samples, we performed enrichment analysis based on FANTOM5 Sample Ontology (FF ontology). The question here is “in which type of samples the promoter is more active”. To answer this question, we compared expressions (TPMs) in the samples associated with a sample ontology term and the rest of the samples by using the Mann-Whitney rank sum test. To summarize ontologies enriched in this co-expression cluster, we ran the same analysis on an averaged expression profile of all promoters that make up. <b>Analyst:</b> Hideya Kawaji <br><br>links to source dataset<br><br>cell_data<br>uberon_data<br><br>

Cell Type
Ontology termp-valuen
myeloid leukocyte8.22e-3276
granulocyte monocyte progenitor cell2.49e-3171
macrophage dendritic cell progenitor4.76e-2965
monopoietic cell8.75e-2863
monocyte8.75e-2863
monoblast8.75e-2863
promonocyte8.75e-2863
myeloid lineage restricted progenitor cell8.93e-2870
myeloid cell3.02e-24112
common myeloid progenitor3.02e-24112
CD14-positive, CD16-negative classical monocyte6.08e-2442
classical monocyte2.31e-2045
leukocyte4.33e-11140
hematopoietic oligopotent progenitor cell3.02e-09165
hematopoietic multipotent progenitor cell3.02e-09165
hematopoietic lineage restricted progenitor cell6.58e-09124
hematopoietic stem cell2.87e-08172
angioblastic mesenchymal cell2.87e-08172
mesenchymal cell4.87e-08358
hematopoietic cell8.03e-08182
nongranular leukocyte1.10e-07119
connective tissue cell4.44e-07365
multi fate stem cell5.30e-07430
Uber Anatomy
Ontology termp-valuen
immune system3.60e-28115
bone marrow2.78e-2780
hemolymphoid system2.45e-26112
hematopoietic system9.08e-26102
blood island9.08e-26102
bone element1.27e-2386
skeletal element5.20e-20101
skeletal system5.20e-20101
lateral plate mesoderm2.56e-13216
musculoskeletal system2.26e-12167
adult organism8.00e-10115
anatomical system2.01e-08625
anatomical group2.32e-08626
tissue1.73e-07787
organ3.43e-07511


Overrepresented TFBS (DNA) motifs on this co-expression cluster<b>Summary:</b>The values shown are the p-values for overrepresentation of the motif in this coexpression cluster. So a small p-value means a strong overrepresentation. <b>Analyst:</b> Michiel de Hoon <br><br>link to source data <br> Novel motifs <br>data <br><br> Jaspar motifs <br>data

Novel motifs



JASPAR motifs

Motifs-log10(p-value)

{{{tfbs_overrepresentation_jaspar}}}



ENCODE TF ChIP-seq peak enrichment analysis<b>Summary:</b> For each TF and each co-expression cluster, the number of promoters with ENCODE TF ChIP signal was compared with the rest of promoters from the robust set using Fisher's exact test. Clusters with significant ChIP enrichment (q <= 0.05) after Benjamini-Hochberg correction were retained. <br><b>Analyst:</b> Erik Arner<br><br>link to source dataset<br><br>data

No analysis results for this cluster

Relative expression of the co-expression cluster<b>Summary:</b>Co-expression clusters are compared against FANTOM5 samples to obtain relative expression. <br><b>Analyst:</b>NA<br><br>link to data source<br> data

"{{{coexpression_dpi_cluster_scores_median}}}" is not a number.

Retrieved from "http://f5-webapp4.gsc.riken.jp/resource_browser/index.php?title=Coexpression_cluster:C166&oldid=1851401"